SCHEMBL14246746

SCHEMBL14246746

Cc1ccc(N(C)C(=O)c2sc3ccccc3c2Cl)c(C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CD274 Q9NZQ7 1/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ MAPT P10636 2/20 0.51
▸ TP53 P04637 1/20 0.51
▸ RXFP1 Q9HBX9 1/20 0.51
▸ NPSR1 Q6W5P4 3/20 0.50
▸ POLB P06746 2/20 0.50
▸ NLRP1 Q9C000 1/20 0.50
▸ MCL1 Q07820 2/20 0.49
▸ PTPN7 P35236 1/20 0.48
▸ PTPN12 Q05209 1/20 0.48
▸ PTPN22 Q9Y2R2 1/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ BCL2L1 Q07817 1/20 0.48
▸ F10 P00742 6/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14246767 0.82 CD274 (0.59) CD274SMN1; SMN2MAPTTP53RXFP1
SCHEMBL15292793 0.80 MCL1 (0.52) CD274SMN1; SMN2MAPTTP53RXFP1
SCHEMBL14246744 0.80 DYRK1A (0.54) CD274SMN1; SMN2MAPTTP53RXFP1
SCHEMBL14317867 0.79 CD274 (0.56) CD274SMN1; SMN2MAPTTP53RXFP1
SCHEMBL14317877 0.79 NPSR1 (0.49) CD274SMN1; SMN2MAPTTP53RXFP1
SCHEMBL14246842 0.78 NPSR1 (0.49) CD274SMN1; SMN2MAPTTP53RXFP1
SCHEMBL14305722 0.78 CD274 (0.63) CD274SMN1; SMN2MAPTTP53RXFP1
SCHEMBL14246812 0.77 NPSR1 (0.50) CD274SMN1; SMN2MAPTTP53RXFP1
SCHEMBL14246841 0.77 NPSR1 (0.46) CD274SMN1; SMN2MAPTTP53RXFP1
SCHEMBL14317880 0.77 SMN1; SMN2 (0.48) CD274SMN1; SMN2MAPTTP53RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 — — US disclosed
US-9334256-B2 Agents and methods for treating ischemic and other diseases NONO INC. (CA) 2016-05-10 — — US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 — — US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 — — US disclosed
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases NONO INC. (CA) 2014-08-07 — — US disclosed
EP-2720695-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NoNO Inc. (CA) 2014-04-23 — — EP disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 — — WO disclosed
WO-2012174488-A2 AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES NONO, INC. (CA) 2012-12-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221423-A1 Agents And Methods For Treating Ischemic And Other Diseases TRPM7, TRPM8, TRPM5 CD274 3735/4885SMN1; SMN2 2627/4885MAPT 1802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback